Kestra Medical Technologies (NASDAQ:KMTS) Given Buy Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research report sent to investors on Wednesday,Benzinga reports. They currently have a $32.00 price target on the stock.

A number of other analysts have also recently commented on the company. The Goldman Sachs Group set a $24.00 price target on Kestra Medical Technologies in a research report on Friday, January 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Wells Fargo & Company lifted their target price on Kestra Medical Technologies from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 target price on Kestra Medical Technologies in a research report on Friday, December 12th. Finally, Piper Sandler increased their price target on shares of Kestra Medical Technologies from $27.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, December 12th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kestra Medical Technologies has an average rating of “Moderate Buy” and a consensus target price of $29.00.

Kestra Medical Technologies Trading Down 7.4%

NASDAQ KMTS opened at $19.58 on Wednesday. Kestra Medical Technologies has a 12-month low of $13.25 and a 12-month high of $30.00. The company has a fifty day simple moving average of $24.19 and a two-hundred day simple moving average of $24.53. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.26. The stock has a market cap of $1.14 billion and a P/E ratio of -4.94.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 74.66%. The company had revenue of $24.55 million for the quarter. The business’s revenue for the quarter was up 62.7% compared to the same quarter last year.

Insider Buying and Selling

In related news, insider Traci S. Umberger sold 10,500 shares of Kestra Medical Technologies stock in a transaction on Monday, December 29th. The shares were sold at an average price of $26.69, for a total value of $280,245.00. Following the sale, the insider owned 136,633 shares of the company’s stock, valued at approximately $3,646,734.77. This trade represents a 7.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $25.60, for a total transaction of $384,000.00. Following the completion of the sale, the insider directly owned 379,786 shares of the company’s stock, valued at approximately $9,722,521.60. The trade was a 3.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 55,500 shares of company stock valued at $1,405,095 over the last 90 days. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Several institutional investors have recently modified their holdings of KMTS. Invesco Ltd. purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter worth about $239,000. Perceptive Advisors LLC purchased a new position in Kestra Medical Technologies in the 4th quarter valued at about $7,558,000. Janus Henderson Group PLC acquired a new stake in Kestra Medical Technologies in the 4th quarter worth about $300,000. Balyasny Asset Management L.P. boosted its holdings in Kestra Medical Technologies by 80.6% in the 4th quarter. Balyasny Asset Management L.P. now owns 6,915 shares of the company’s stock worth $183,000 after buying an additional 3,086 shares during the last quarter. Finally, Burkehill Global Management LP purchased a new stake in Kestra Medical Technologies during the 4th quarter worth approximately $1,326,000.

Trending Headlines about Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Revenue growth and raised guidance: Q3 revenue was $24.55M, up 62.7% year‑over‑year, and management raised FY2026 revenue guidance to $93M — evidence of accelerating sales and market expansion. GlobeNewswire Release
• Positive Sentiment: Analyst support: BTIG reaffirmed a “buy” and set a $32 price target (~60%+ upside from current levels), which can provide investor confidence and buying interest. Benzinga
• Positive Sentiment: Management commentary highlights expansion and margin progress on the earnings call, which supports the upbeat guidance and growth narrative. Seeking Alpha Transcript
• Neutral Sentiment: Full call/transcript and press materials are available for deeper due diligence — useful for investors who want to parse cadence, customer wins and margin drivers. Yahoo Finance Transcript
• Negative Sentiment: EPS miss and continued unprofitability: Reported EPS of ($0.61) missed the consensus ($0.60) by $0.01; the company still shows negative net margin (~‑171.9%) and negative ROE, underscoring that growth is not yet translating into profitability. MarketBeat Earnings Summary
• Negative Sentiment: Market reaction/technicals: Shares are trading below both the 50‑ and 200‑day moving averages and volume is well above average, indicating sellers dominated today as investors digested the mixed report. (Balance sheet liquidity is solid, but profitability concerns and the EPS miss likely drove the sell‑off.)

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.